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ABSTRACT 
   
     Evaluation of the factors associated with treatment process of leukemia and comparison with current 
related approaches in developed countries can present a good indicator to assess the weak and strong points 
in healthcare system of our country in leukemia treatment. The objective of this research is general and 
specific description of the challenges and shortcomings in Iranian healthcare system and monitoring of 
hematologic malignancies as well as comparison with developed countries. Our study is a descriptive-cross-
sectional study. 100 hemato-oncologist , pathologists, and faculty members throughout the country were 
selected by random cluster sampling. Data collected using questionnaires with Cronbach's alpha coefficient 
of 0.76 . SPSS and Chi-square test were used for data analysis. According to the specialists, lack of 
advanced diagnostic facilities as well as cell and BM banks together with high treatment expenses are the 
main factors contributing to poor treatment processes in Iran, which are far from worldwide standards. 
The use of novel currently methods used in developed countries for leukemia treatment, financial and 
psychological support of patients under treatment , making underprivileged provinces well-equipped 
,balanced  specialist service distribution relative to capital city either in diagnosis or treatment are factors 
which makes system standardized. Moreover, integrated institutional work in relation to leukemia incidence 
and statistical analysis of mortality and morbidity rate can pave the way for reducing and eliminating the 
problems in diagnosis and treatment of leukemia patients.  
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INTRODUCTION 
    The uncontrollable effects of malignant 
diseases and those mental and economical effects 
on a society is well obvious, and currently they 
considered as one of the most significant health 
problems in the world [1]. It can be stated that 
malignancies are the second and third cause of 
mortality in developed and underdeveloped 
countries, respectively [2]. It is estimated that 
with uncontrollable growth of human exposure to 
environmental risk factors, we will observe the 
higher incidence of cancers in the following 
years, as a result, the chance for develop the 
cancer for each person would be 50% to 60% in 
2050 [3].Statistically, as most countries in the 
world, the rate of cancers in Iran is increasing. In 
some cases this prevalence is higher than the 
standard levels [4]. according to the Iran ministry 
of health report published by 2007 ( based on the 
report of Pathology center, exclusively), cancers 
of skin,  breast, stomach, colorectal, liver, 
hematopoietic system, esophagus, prostate, lung, 
brain, and the central nervous system (CNS) are 
the most prevalent malignancies in Iran [3]. 
among these, hematological malignancies with 
5.7% incidence ranked sixth , showing 1.3 
increase relative to 2005 report. Currently based 
on the standards of  health organizations, 
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preventive strategies show considerable priority 
than treatment protocols. Various molecular 
methods, including microarray analysis, 
polymerase chain reaction (PCR), biocheeps, etc 
designed and marketed by which individuals in 
risk of different diseases can be detected prior to 
their predisposing in order to prevent their 
involvement. In fact the overwhelming costs of 
treatment will be obviated through these strategies 
and it will be a remarkable help for personal and 
social health. Therefore, presently, determining 
the national strategies for cancer prevention and 
control, especially  blood cancers is regarded as 
one of the social health priorities. It is clear that 
punctilious and accurate diagnosis, itself, can be a 
good start point for a desired treatment process 
[5]. Today, blood cancers or leukemias constitute 
about 8 percent of total neoplastic disorders in the 
human population, and considered as the fifth 
prevalent cancer in the world [6-8]. Treatment of 
hematological malignancies is far complicated 
and depends on the age, health status, type of 
malignancy, and the rate of it´s distribution [9-
14]. Through all the required options for a desire 
diagnosis and treatment process, facilities and 
equipments are noteworthy. In the other word 
Providing the required diagnostic equipments is 
prerequisite for other treatment needs [15]. 
All over the world, diagnosis of hematological 
malignancies is primarily accomplished by 
physical examination, laboratory findings, 
including morphological evaluations ( peripheral 
blood and bone marrow films), cytogenetics, 
immunophenotyping, flow cytometry, FISH, 
cytochemistry, and a variety of molecular 
methods [16]. 
Remedies, currently used to treat the leukemias, 
consist of chemotherapy [17-19], biotherapy ( or 
immunotherapy in which the immune system 
becomes more potent against cancer cells by 
means of especial substances, thus prevent cancer 
progression) [20], bone marrow transplantation 
[21], and using stem cells [22-24]. Bone marrow 
transplantation is accomplished as either 
autologous and allogenous, and it can be fulfilled 
through both bone marrow and peripheral blood 
as the source of stem cells [25]. The purpose of 
this method is to put the patient in the remission 
phase in order to obtain a comparatively perfect 
and irreversible cure. Today developed countries 
have been able to subside the mortality rates due 
to blood cancers, by using the novel methods 
based on elimination of aggressive methods, and 
diminishing the costs and wasting the time 
compared with traditional methods. Of these 
novel methods are nutritional support for patients 
[26,27] and pain management [28,29] of leukemic 
patients. Indeed, the goal of these strategies are to 
enhance the patients cooperation with the 
treatment team during the diagnosis and treatment 
course. The pain management might consist of 
radiotherapy for bone pains, opioid drugs, 
massage therapy, and using the anesthetic drugs 
[21]. It is worthwhile to say that unsatisfactory 
complications, such as nausea and vomiting 
emanating from chemotherapy for cancers, causes 
psychological resentment which could 
overshadow the treatment protocols, as well. 
Recent advancements have resulted in 
development of anti nausea drugs, including 
Kisseptin 1 (K1) receptor antagonists, and 5-
hydroxytriptamin 3 (5-HT3) which are rather 
expensive [30]. 
Today one of the most serious problems to 
treatment is high expenditures. Hence many 
supportive institutes have been established for 
mental, psychological, and financial aids, but their 
activities have not met the demand [15]. This 
institutes are often charities and social, thus no 
one can have great expectations from them. In this 
situation the governmental as well as 
nongovernmental supports  become more 
noticeable. These supports must be focused on the 
requirements previously mentioned for cancer 
patients [31]. 
According to this fact that no study has made so 
far on problems of blood malignancy treatment, 
and regarding that developed countries shifted 
their treatment approaches toward novel, 
nonaggressive methods, this study was made as 
the first thorough and detailed investigation into 
the problems of Iran health system by iranian 
collaboration of hemato-oncology and pathology 
specialists. We hope that the findings of this study 
would reflect the limitations existed in Iran in 
leukemia therapy, and to motivate further 
complimentary studies. Conclusively, this study 
will reflect the current leukemia therapy problems 
in Iran and will suggest solutions with the hope of 
improving the social health. 
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MATERIALS AND METHODS 
    The researcher made questionnaire was 
designed and the validity and stability were 
evaluated. The face validity of the test for 30 
cases was taken based on expert´s perspectives, 
and required amendments were made. The content 
validity was also provided according to the 
specialists and most up to date version of 
hematology and oncology  references. The test 
stability also calculated using Cronbach´s alpha 
coefficient of 0.76 with authentic validation 
which indicated that the questions had strong 
correlation. 
The study is a descriptive- cross sectional with the 
population consist of 100 members of hemato- 
oncology and pathology specialists working in 
educational as well as personalized hospitals, and 
the academic staff throughout the country. The 
research units were determined as many as 100 
members by count and exclusively selected 
according to their inclination to attend in our 
study. Data collection was made through 
questionnaire and the items were divided into two 
main groups by a review on previous studies. In 
the first group of questions we designed 
demographic information (eg .age, sex, living 
province, university, and the last educational 
degree). For the second part of questions we 
considered some questions on treatment of 
leukemia in Iran, such as treatment of patient at 
specialty health center in the patient living city, 
presence of novel diagnostic facilities, the causes 
of delayed treatment, presence or absence of a 
specialty bone marrow bank in the specialist´s 
living city, using of novel, FDA approved drugs 
used for leukemia treatment, the propagation of 
novel treatment methods like cell therapy in the 
province of specialist´s locals service, balance in 
distribution of equipments, specialists, and other 
facilities in proportion to the leukemia patients 
distribution throughout the country, Look back 
process after early treatment, and costs of 
leukemia treatment. Finally we designed some 
questions regards to coherent community deal 
with statistical information about incidence and 
mortality rate in the province of health service. It 
is important to mention that all the questions were 
designed in three choice form, and according to 
the developed countries criteria and approaches 
regarding to leukemia treatment. The quantitative 
information resulted from the primary 
examination of the questionnaire were analyzed 
by SPSS and Chi-square test. 
 
RESULTS 
     The population of study consisted of 100 
members with the age range about 29-72 (mean 
age, 44 years) constituted of  62% male and 38% 
female. Of these, the percent of hemato- 
oncologists and pathologists were 38% and 16%, 
respectively.  The related items and results from 
three choice questions are indicated in table 1. 
According to the results, only about 3% of 
specialists stated that healthcare center in their 
province is able to provide complete treatment 
facilities, and 49% asserted that the local health 
centers cannot fulfill the requirements. 
Furthermore, about 48%  believed that there is 
trivial facilities for treatment of leukemia patients 
in their province. Overall evaluation of diagnostic 
facilities in Iran compared with developed 
countries indicated the high levels of differences. 
49% of specialists have already well addressed 
the lack of novel diagnostic facilities and its 
relation to delayed treatment of patients. 
Interestingly, most of these experts were those 
who work in level 2 and 3 cities (deprived 
provinces which are far from the capital). In this 
regard 31% asserted that in addition to the 
shortcoming of novel diagnostic equipments, 
there are some other factors overshadowing the 
punctual treatment of patients. In contrast, 
approximately 20%  of specialists believed that 
there is no association between shortage of novel 
techniques and delayed treatment of their patients. 
Regarding to the other group of questions focused 
on the propagation of novel treatment methods 
like cell therapy in the patient´s local service, 
about half of specialists asserted the 
outperformance of novel treatment methods in the 
patient province, 31% mentioned the limit 
performance, and only 19% claimed the presence 
of required facilities to perform these methods in 
their working province. In relation to the use of 
novel, FDA approved drugs used for leukemia 
therapy which routinely prescribed in developed 
countries, almost 55 percent of specialists 
acknowledged that they do not use these drugs to 
treat their patients, while about 27% mentioned 
that they prescribe theses drugs narrowly, and 
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according to the answers of 18% these drugs have 
been persistently used to treat their patients in 
Iran. Presence or absence of a bone marrow bank 
in the working province of specialists for 
treatment of needed patients were also regarded in 
the other part of questionnaire and the related 
results demonstrated that 63% of individuals 
suffer from shortcoming of a bone marrow bank. 
Contrary, other 37% confirmed the availibility of 
bone marrow bank. It is worthwhile to mention 
that the later group was primarily from level 1 
provinces (like Tehran, Esfahan, Shiraz, Mashad, 
and Tbriz). In the following questions the balance 
of equipments, facilities and other treatment 
facilities distribution in different provinces were 
asked and the obtained results indicated that 63 
percent of specialists believed the unbalanced 
distribution of diagnostic and treatment facilities 
among different cities. They believe that required 
facilities are concentrated in the large cities and 
the patients are referred to these cities for 
treatment. In this study, evaluation of 
overwhelming costs and their effects on patient 
treatment course demonstrated shocking results, 
so that the majority of specialists (more than 
70%) presented that staggering costs is one of the 
most tremendous cause to make people reluctant 
to follow their treatment procedure and thereby to 
the failure  this process. In other question 
associated with the presence of information about 
the epidemiology and mortality rate due to blood 
cancers in the related provinces, 46 percent of 
experts (almost half of the assessing population) 
emphasized the lack of an accurate and reliable 
document in this regard, and 39 percent were also 
believed that these data are recorded partially and 
incoherently in their working province. One of the 
most significant questions asked on the 
questionnaire was addressing the fallow up and 
look back status of patients after treatment as this 
item is one of the integral part of treatment 
process in developed countries. Data resulted 
from this part of questionnaire showed that 80 
percent of physicians perfectly fallow their 
patients after treatment, and 15 percent partially 
assess their patient full treatment process. In this 
case, almost 5 percent of specialists also stated 
that they did not visit their patients after early 
treatment.  
 
Table 1. items associated to 15 asked questions on the questionnaire and related results after interpretation by related 
software. The questions are condensed as 9 main topics here. 
Items and the related percents 
Yes Partially No 
Total 
score 
Complete treatment of patients in the living city. 3 48 49 100 
Prevalence of using novel methods to treat the patient in the specialist´s living 
province. 
19 31 50 100 
balance of facilities and  specialist’s distribution with the leukemia patients around 
the country. 
2 35 63 100 
Using of novel, FDA approved drugs for leukemia therapy routinely used in 
developed countries. 
18 27 55 100 
Is lack of novel diagnosis facilities the cause of delayed treatment of patients? 49 31 20 100 
Presence of an equipped bone marrow bank in the working province. 37 0 63 100 
Is the Costs of of treatment a main reason preventing the patient to persist their full 
treatment course? 
73 21 6 100 
Are the patients acceptably followed up after their early treatment? 80 15 5 100 
Presence of accurate and reliable statistic documents on the incidence of leukemia 
and it´s mortality rate in the working province. 
15 39 46 100 
 
DISCUSSION 
    The aim of this study is to determine the 
problems and shortcomings in treatment of 
leukemia patients, and related requirements. The 
finding of our study evidenced that of the current 
obstacles on diagnosis and treatment of patients  
with blood cancers are the lack of diagnostic and 
treatment facilities, non uniform distribution of 
the facilities and specialist in the country, high 
costs of treatment and depriving from novel 
methods in leukemia treatment. Early 
establishment of the required diagnostic methods  
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as a basic item in treatment process is a 
prerequisite for the accommodation of different 
treatment needs [32]. Based on results of this 
study, almost half of the specialists in Iran 
consider the shortage of novel diagnostic facilities 
as one of the contributors of delayed start of their 
patient treatment, and interestingly, the same 
specialists believe that the leukemia therapy is 
unsuccessful in their province. About 63 percent 
of experts attributed this problem to the 
unbalanced distribution of diagnostic equipments 
and treatment facilities through the country, 
which indicates that accessibility of advanced 
diagnostic services is the integral part in early 
treatment of leukemia patients. These shortages 
are more sensible in the case of flow cytometry 
devices, molecular diagnosis, and cytogenetic 
analysis [32]. The molecular diagnosis, mostly 
made in large cities, such as Tabriz, Tehran, 
Shiraz, Khorasan Razavi, and Kerman, while 
small cities are deprived from these facilities, and 
patient´s samples are sent to large provinces in 
order to diagnosis.  
Thus in addition to wasting the time and 
expenses, this incongruence distribution results to 
delayed diagnosis and treatment process. Majority 
of Iran specialists do not initiate the treatment 
process before definite diagnosis or they suffice 
the diagnosis by nonspecific methods based on 
findings from the peripheral blood and bone 
marrow films, or in some cases they prefer to treat 
the patient through nonspecific remedies which in 
turn can leads to inaccurate diagnosis and 
treatment, thereby might have irreversible 
complications for patients [32].  
Treatment methods currently used to combat the 
blood malignancies consist of chemotherapy [17-
19], biotherapy [20], bone marrow transplantation 
[21], and stem cell therapy which commonly 
accomplished in most health centers around the 
world. In developed countries, in addition to 
accessibility to mentioned therapeutic choices, 
specialists are seeking to present more 
inexpensive and nonaggressive methods like 
nutritional supports and pain management during 
treatment course [28-29], moreover they have 
managed to utilize novel molecular therapies for 
leukemia. Considering these facts, in this study 
we have demonstrated that 55 percent of 
specialists admited that they do not prescribe 
novel, FDA approved drugs routinely used in 
developed countries for treatment of leukemia 
patients. In the other hand 50% of experts asserted 
that they do not use modern methods for 
treatment of their leukemia patients in the 
working province. furthermore, accessibility to 
these therapeutic options alongside with current 
therapies results to remarkable quench of the 
mortality rate due to blood cancers.  
Today bone marrow transplantation is also one of 
the most common approaches for leukemia 
treatment especially for all the sectors of society 
around the world [21]. To fulfill this goal finding 
the compatible donor is the main part of the 
process. Thus presence of a far- reaching bone 
marrow bank is one of the most essential needs 
for bone marrow transplantation in every 
specialty center. The findings of our study dealing 
with the existence of a especial bone marrow 
bank in different provinces of country has a 
sobering fact and that is, according to perspective 
of 63 percent of experts one of the most important 
problems in treatment of leukemia patients who 
need for bone marrow transplantation is 
inaccessibility to a bone marrow bank in the 
working center. In this situation patients, 
inevitably refer to the centers possessing these 
facilities and in turn make some difficulties for 
these equipped centers.  
Furthermore this can affects the quality of 
treatment for the patients. Our investigation on 
one of the largest center for treatment of blood 
disorders in Tehran, Shariati hospital, showed that 
because of insufficient facilities, hospitalized 
patients inevitably released before the schedule 
time, otherwise the other patients waiting for 
services may die. Moreover due to release of 
patients before the schedule time, there is no 
guarantee for their survival. It should be stated 
that shortages of experienced specialists and other 
staff in proportion to the mass of visitors, low 
levels of services, and long time waiting of 
patients to reach the schedule time for 
transplantation are the defects, which according to 
the medical staffs, lead to situation in which the 
mentioned process would be far from the 
worldwide standard levels. Considering these 
facts, it can be said that development of bone 
marrow banks with suitable distribution in health 
center all over the country as the first step can 
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effectively pave the way to solve the difficulties 
facing with bone marrow transplantation.  
In the case of cost payment for diagnostic and 
treatment services by the patients in Iran the 
considerable results of this study and the previous 
study of our research team is that, majority of 
patients afford the costs of diagnosis, however in 
treatment phase especially in purchasing the 
required import drugs, they faced with different 
financial problems. In current study, 93 percent of 
specialists considered these cumbersome costs as 
one of the main reasons preventing the leukemia 
patients from initiating and following up their 
treatment courses in Iran. Eloquent study made by 
our colleagues also verified that one of the most 
crucial concerns of cancer patients is the lack of 
sufficient communities and institutes to provide 
financial support from them [15]. Generally, 
majority of related communities in Iran are 
charities and social which mainly focused on 
emotional and social aspects of disease and no 
one can have great expectations from them to 
settle down the financial difficulties the leukemia 
patients involved in. our study proved that the 
supports either in leukemia diagnosis or treatment 
from governmental and personalized institutes as 
well as different insurance organizations can play 
a critical role to keep pace with other countries 
toward the modern global standards. In a part of 
our study we demonstrated that one of the current 
problems in treatment of leukemia patients in the 
country, according to specialists, is lack of an 
appropriate mechanism for receiving the special 
drugs. This problem roots in the fact that the 
insurance organizations do not undertake the costs 
of these drugs, and although the patients receive 
the governmental subsidies, they cannot afford the 
debilitating costs to persist the treatment course. 
In the case of monitoring the patient by specialists 
after early treatment, we found out that 
approximately 80 percent of physicians in Iran 
take their patients under persistent consideration, 
and this fact can be remarkable and a desired  
result. Whereas, 20 percent of clinicians attending 
in our study attributed their proportional 
negligence to this believe that monitoring of their 
patients after treatment was not necessary.  
These thinkable results showed that the country is 
benighted from the modern standard levels. 
Finally according to our investigation, lack of an 
efficient and coherent statistical study regards to 
the correlation of different type of leukemia and 
the mortality rate due to blood malignancies is 
sensible which itself can be resulted from 
indifference of government to the diagnosis, 
prevention and control of leukemia in Iran. 
considering the observing of the current realities 
as well as growing incidence of malignancies and 
their mortality, we need to concentrate our 
financial and social supports on improving the 
levels of treatment. 
 
CONCLUSION 
     According to the results of this study we can 
infer that most of the problems associated with 
leukemia therapy in Iran is rooted in shortage of 
modern facilities,and non- uniform distribution of 
facilities in the country, while developed 
countries have passed these obstacles and are 
moving toward more specialized and novel 
techniques to cure he patients by dedication of 
suitable policies. Indeed, by utilizing the novel 
methods used in other developed countries for 
treatment of leukemia, elucidation of accurate and 
up to date incidence and epidemiology of 
leukemia in Iran, psychological and financial 
supports of patients during the treatment course, 
focusing of governmental policies on drug 
supports, equip all the provinces with modern 
health systems especially bone marrow banks, as 
well as increasing the members of specialized 
healthcare centers and experienced physicians, we 
hope to reach the levels of treatment to the 
modern global standards and to appropriately 
respond one of the most substantial concerns of 
leukemia patients and society. 
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